Antitumor activity from the combined application of poly(I:C) and chemotherapeutics in human metastatic pharyngeal cell lines

Chemotherapy

Volumn 57, Issue 6, 2012, Pages 460-467

  Matijević, Tanja ^a   Kirinec, Gabriela ^a   Pavelić, Jasminka ^a  

^a RUDER BO KOVI INSTITUTE   (Croatia)

Author keywords

Anticancer therapy; Apoptosis; Chemotherapy; Poly(I:C); Toll like receptor 3

Indexed keywords

CASPASE 3; CASPASE 7; CISPLATIN; FLUOROURACIL; HYDROXYUREA; METHOTREXATE; POLYINOSINIC POLYCYTIDYLIC ACID; SMALL INTERFERING RNA; TOLL LIKE RECEPTOR 3;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CELL GROWTH; CYTOTOXICITY; DRUG INHIBITION; HUMAN; HUMAN CELL; METASTASIS; PRIORITY JOURNAL;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CELL LINE, TUMOR; CELL PROLIFERATION; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; PHARYNGEAL NEOPLASMS; POLY I-C;

EID: 83755206819     PISSN: 00093157     EISSN: 14219794     Source Type: Journal    
DOI: 10.1159/000334122     Document Type: Article

References (42)

1. Medzhitov R, Preston-Hurlburt P, Janeway CA Jr: A human homologue of the Drosophila Toll protein signals activation of adaptive immunity. Nature 1997; 388: 394-397. (Pubitemid 27334820)
2. Goto Y, Arigami T, Kitago M, Nguyen SL, Narita N, Ferrone S, Morton DL, Irie RF, Hoon DS: Activation of Toll-like receptors 2, 3, and 4 on human melanoma cells induces inflammatory factors. Mol Cancer Ther 2008; 7: 3642-3653.
3. He W, Liu Q, Wang L, Chen W, Li N, Cao X: TLR4 signaling promotes immune escape of human lung cancer cells by inducing immunosuppressive cytokines and apoptosis resistance. Mol Immunol 2007; 44: 2850-2859. (Pubitemid 46412506)
4. Huang B, Zhao J, Shen S, Li H, He KL, Shen GX, Mayer L, Unkeless J, Li D, Yuan Y, Zhang GM, Xiong H, Feng ZH: Listeria monocytogenes promotes tumor growth via tumor cell Toll-like receptor 2 signaling. Cancer Res 2007; 67: 4346-4352. (Pubitemid 46815083)
5. Xie W, Wang Y, Huang Y, Yang H, Wang J, Hu Z: Toll-like receptor 2 mediates invasion via activating NF-+ B in MDA-MB-231 breast cancer cells. Biochem Biophys Res Commun 2009; 379: 1027-1032.
6. Salaun B, Coste I, Rissoan MC, Lebecque SJ, Renno T: TLR3 can directly trigger apoptosis in human cancer cells. J Immunol 2006; 176: 4894-4901.
7. Salaun B, Lebecque S, Matikainen S, Rimoldi D, Romero P: Toll-like receptor 3 expressed by melanoma cells as a target for therapy? Clin Cancer Res 2007; 13: 4565-4574. (Pubitemid 47219727)
8. Khvalevsky E, Rivkin L, Rachmilewitz J, Galun E, Giladi H: TLR3 signaling in a hepatoma cell line is skewed towards apoptosis. J Cell Biochem 2007; 100: 1301-1312. (Pubitemid 46480411)
9. Paone A, Starace D, Galli R, Padula F, De Cesaris P, Filippini A, Ziparo E, Riccioli A: Tolllike receptor 3 triggers apoptosis of human prostate cancer cells through a PKC-dependent mechanism. Carcinogenesis 2008; 29: 1334-1342.
10. Nomi N, Kodama S, Suzuki M: Toll-like receptor 3 signaling induces apoptosis in human head and neck cancer via survivin associated pathway. Oncol Rep 2010; 24: 225-231.
11. Field AK, Tytell AA, Lampson GP, Hilleman MR: Inducers of interferon and host resistance. II. Multistranded synthetic polynucleotide complexes. Proc Natl Acad Sci USA 1967; 58: 1004-1010.
12. Alexopoulou L, Holt AC, Medzhitov R, Flavell RA: Recognition of double-stranded RNA and activation of NF-B by Toll-like receptor 3. Nature 2001; 413: 732-738. (Pubitemid 33009951)
13. Matsumoto M, Kikkawa S, Kohase M, Miyake K, Seya T: Establishment of a monoclonal antibody against human Toll-like receptor 3 that blocks double-stranded RNAmediated signaling. Biochem Biophys Res Commun 2002; 293: 1364-1369. (Pubitemid 34681026)
14. Yoneyama M, Kikuchi M, Natsukawa T, Shinobu N, Imaizumi T, Miyagishi M, Taira K, Akira S, Fujita T: The RNA helicase RIG-I has an essential function in double-stranded RNA-induced innate antiviral responses. Nat Immunol 2004; 5: 730-737. (Pubitemid 39023305)
15. Matijevic T, Marjanovic M, Pavelic J: Functionally active Toll-like receptor 3 on human primary and metastatic cancer cells. Scand J Immunol 2009; 70: 18-24.
16. Miyake T, Kumagai Y, Kato H, Guo Z, Matsushita K, Satoh T, Kawagoe T, Kumar H, Jang MH, Kawai T, Tani T, Takeuchi O, Akira S: Poly I:C-induced activation of NK cells by CD8 + dendritic cells via the IPS-1 and TRIF-dependent pathways. J Immunol 2009; 183: 2522-2528.
17. Herbst-Kralovetz MM, Pyles RB: Quantification of poly(I:C)-mediated protection against genital herpes simplex virus type 2 infection. J Virol 2006; 80: 9988-9997. (Pubitemid 44522593)
18. McCartney S, Vermi W, Gilfillan S, Cella M, Murphy TL, Schreiber RD, Murphy KM, Colonna M: Distinct and complementary functions of MDA5 and TLR3 in poly(I:C)-mediated activation of mouse NK cells. J Exp Med 2009; 206: 2967-2976.
19. Jasani B, Navabi H, Adams M: Ampligen: a potential Toll-like 3 receptor adjuvant for immunotherapy of cancer. Vaccine 2009; 27: 3401-3404.
20. Lacour J, Laplanche A, Malafosse M, Gallot D, Julien M, Rotman N, Guivarc'h M, Roullet-Audy JC, Lasser P, Hautefeuille P, et al: Polyadenylic-polyuridylic acid as an adjuvant in resectable colorectal carcinoma: a 6 1 / 2 year follow-up analysis of a multicentric double-blind randomized trial. Eur J Surg Oncol 1992; 18: 599-604. (Pubitemid 23052271)
21. Laplanche A, Alzieu L, Delozier T, Berlie J, Veyret C, Fargeot P, Luboinski M, Lacour J: Polyadenylic-polyuridylic acid plus locoregional radiotherapy versus chemotherapy with CMF in operable breast cancer: a 14-year follow-up analysis of a randomized trial of the Fédération Nationale des Centres de Lutte contre le Cancer (FNCLCC). Breast Cancer Res Treat 2000; 64: 189-191. (Pubitemid 32010336)
22. Aota K, Azuma M, Yamashita T, Tamatani T, Motegi K, Ishimaru N, Hayashi Y, Sato M: 5-Fluorouracil induces apoptosis through the suppression of NF-B activity in human salivary gland cancer cells. Biochem Biophys Res Commun 2000; 273: 1168-1174. (Pubitemid 30481097)
23. Johnson CA, Forster TH, Winterford CM, Allan DJ: Hydroxyurea induces apoptosis and regular DNA fragmentation in a Burkitt's lymphoma cell line. Biochim Biophys Acta 1992; 1136: 1-4.
24. Henkels KM, Turchi JJ: Cisplatin-induced apoptosis proceeds by caspase-3-dependent and -independent pathways in cisplatin-resistant and -sensitive human ovarian cancer cell lines. Cancer Res 1999; 59: 3077-3083. (Pubitemid 29316005)
25. Celtikci B, Lawrance AK, Wu Q, Rozen R: Methotrexate-induced apoptosis is enhanced by altered expression of methylene tetrahydrofolate reductase. Anticancer Drugs 2009; 20: 787-793.
26. Matijevic T, Pavelic J: The dual role of TLR3 in metastatic cell line. Clin Exp Metastasis 2011; 28: 701-712.
27. Jiang Q, Wei H, Tian Z: Poly I:C enhances cycloheximide-induced apoptosis of tumor cells through TLR3 pathway. BMC Cancer 2008; 8: 12.
28. Taura M, Eguma A, Suico MA, Shuto T, Koga T, Komatsu K, Komune T, Sato T, Saya H, Li JD, Kai H: p53 regulates Toll-like receptor 3 expression and function in human epithelial cell lines. Mol Cell Biol 2008; 28: 6557-6567.
29. Caamano J, Zhang SY, Rosvold EA, Bauer B, Klein-Szanto AJ: p53 alterations in human squamous cell carcinomas and carcinoma cell lines. Am J Pathol 1993; 142: 1131-1139. (Pubitemid 24060589)
30. Kato S, Han SY, Liu W, Otsuka K, Shibata H, Kanamaru R, Ishioka C: Understanding the function-structure and function-mutation relationships of p53 tumor suppressor protein by high-resolution missense mutation analysis. Proc Natl Acad Sci USA 2003; 100: 8424-8429. (Pubitemid 36842561)
31. Taura M, Fukuda R, Suico MA, Eguma A, Koga T, Shuto T, Sato T, Morino-Koga S, Kai H: TLR3 induction by anticancer drugs potentiates poly I:C-induced tumor cell apoptosis. Cancer Sci 2010; 101: 1610-1617.
32. Bourantas KL, Syrou M, Tsiara S, Danella M, Konstantinides P: Combination therapy with interferon alfa-2b and hydroxyurea during the accelerated phase of chronic myelogenous leukemia. Acta Haematol 1996; 95: 117-121. (Pubitemid 26110055)
33. Hehlmann R, Berger U, Pfirrmann M, Hochhaus A, Metzgeroth G, Maywald O, Hasford J, Reiter A, Hossfeld DK, Kolb HJ, Loffler H, Pralle H, Queisser W, Griesshammer M, Nerl C, Kuse R, Tobler A, Eimermacher H, Tichelli A, Aul C, Wilhelm M, Fischer JT, Perker M, Scheid C, Schenk M, Weiss J, Meier CR, Kremers S, Labedzki L, Schmeiser T, Lohrmann HP, Heimpel H: Randomized comparison of interferon-and hydroxyurea with hydroxyurea monotherapy in chronic myeloid leukemia (CML study II): prolongation of survival by the combination of interferon alpha and hydroxyurea. Leukemia 2003; 17: 1529-1537. (Pubitemid 36986954)
34. Makower D, Wadler S: Interferons as biomodulators of fluoropyrimidines in the treatment of colorectal cancer. Semin Oncol 1999; 26: 663-671. (Pubitemid 30013273)
35. Wada H, Nagano H, Yamamoto H, Noda T, Murakami M, Kobayashi S, Marubashi S, Eguchi H, Takeda Y, Tanemura M, Umeshita K, Doki Y, Mori M: Combination of interferon-and 5-fluorouracil inhibits endothelial cell growth directly and by regulation of angiogenic factors released by tumor cells. BMC Cancer 2009; 9: 361.
36. Hand A, Pelin K, Mattson K, Linnainmaa K: Interferon-and interferon-in combination with methotrexate: in vitro sensitivity studies in four human mesothelioma cell lines. Anticancer Drugs 1995; 6: 77-82.
37. Seo KW, Lee HW, Oh YI, Ahn JO, Koh YR, Oh SH, Kang SK, Youn HY: Anti-tumor effects of canine adipose tissue-derived mesenchymal stromal cell-based interferon-gene therapy and cisplatin in a mouse melanoma model. Cytotherapy 2011; 13: 944-955.
38. Nehme A, Julia AM, Jozan S, Chevreau C, Bugat R, Canal P: Modulation of cisplatin cytotoxicity by human recombinant interferon-in human ovarian cancer cell lines. Eur J Cancer 1994; 30A:520-525. (Pubitemid 24171962)
39. Yonekura N, Yokota S, Yonekura K, Dehari H, Arata S, Kohama G, Fujii N: Interferon-downregulates Hsp27 expression and suppresses the negative regulation of cell death in oral squamous cell carcinoma lines. Cell Death Differ 2003; 10: 313-322. (Pubitemid 36582369)
40. Wang Y, Dong L, Bi Q, Ge X, Zhang X, Wu D, Fu J, Zhang C, Wang C, Li S: Beyond antiangiogenesis: intratumorally injected bevacizumab plays a cisplatin-sensitizing role in squamous cell carcinomas in mice. Chemotherapy 2011; 57: 244-252.
41. Wang Y, Bi Q, Dong L, Li X, Ge X, Zhang X, Fu J, Wu D, Li S: Quinacrine enhances cisplatin-induced cytotoxicity in four cancer cell lines. Chemotherapy 2010; 56: 127-134.
42. Pries R, Hogrefe L, Xie L, Frenzel H, Brocks C, Ditz C, Wollenberg B: Induction of c-Mycdependent cell proliferation through Tolllike receptor 3 in head and neck cancer. Int J Mol Med 2008; 21: 209-215. (Pubitemid 351222854)